Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q58971580)
Watch
English
Bisphosphonates
scientific article published on 01 March 2003
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
review article
1 reference
stated in
Europe PubMed Central
title
Bisphosphonates
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
author
Michael McClung
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
author name string
Michael R McClung
series ordinal
1
0 references
publication date
1 March 2003
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
published in
Endocrinology and Metabolism Clinics of North America
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
volume
32
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
issue
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
page(s)
253-271
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
cites work
Bisphosphonates: pharmacology, mechanisms of action and clinical uses
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rationale for the use of alendronate in osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate for the Treatment of Osteoporosis in Men
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Etidronate for treating and preventing postmenopausal osteoporosis.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pamidronate: an unrecognized problem in gastrointestinal tolerability
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Zoledronic acid
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intravenous zoledronic acid in postmenopausal women with low bone mineral density
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Studies of the oral bioavailability of alendronate.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Esophagitis associated with the use of alendronate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Upper gastrointestinal toxicity of alendronate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate-associated esophagitis: endoscopic and pathologic features
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Esophageal stricture associated with alendronate therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate gastric ulcers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of EHDP on fracture healing in dogs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nephrotic syndrome after treatment with pamidronate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Postoperative hypocalcemic tetany caused by fleet® Phospho®-Soda preparation in a patient taking alendronate sodium
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hypoparathyroidism unmasked by alendronate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The acute-phase response after bisphosphonate administration
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Severe oral ulcerations induced by alendronate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate-related oral mucosa ulcerations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Liver damage due to alendronate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pamidronate disodium and possible ocular adverse drug reactions
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Idiopathic orbital inflammation following intravenous pamidronate.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate prevents bone loss in Chinese women with osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate prevents further bone loss in renal transplant recipients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prevention of secondary osteoporosis postmenopause in hemiplegia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intravenous pamidronate attenuates bone density loss after acute spinal cord injury
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
How long should patients with osteoporosis be treated with bisphosphanates?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900079-8
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0889-8529(02)00079-8
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
PubMed publication ID
12699302
1 reference
stated in
Europe PubMed Central
PubMed publication ID
12699302
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699302%20AND%20SRC:MED&resulttype=core&format=json
retrieved
2 November 2019
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit